Comparative Pharmacology
Head-to-head clinical analysis: DIDRONEL versus SKELID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIDRONEL versus SKELID.
DIDRONEL vs SKELID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone, reducing osteoclast activity and inducing osteoclast apoptosis.
SKELID (tiludronate disodium) is a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone and inhibiting osteoclast activity and recruitment.
For Paget disease: 5 mg/kg orally once daily for 6 months, or 5 mg/kg orally once daily for 3 months if retreatment; for heterotopic ossification: 20 mg/kg orally once daily for 2 weeks pre- and 3 months post-surgery; for hypercalcemia of malignancy: 5-10 mg/kg orally once daily for up to 6 months.
400 mg (2 tablets) orally once daily, taken on an empty stomach at least 2 hours before or after food, for 2 hours with 8 oz plain water; avoid other beverages, food, and medications for 2 hours post-dose.
None Documented
None Documented
Terminal elimination half-life ranges from hours to weeks; initial phase 2-6 hours, deep bone phase up to several weeks due to slow release from bone.
Terminal elimination half-life: 10-12 hours (prolonged in renal impairment; no dose adjustment required for mild-moderate impairment but contraindicated in severe impairment [CrCl <30 mL/min])
Renal: 50% unchanged; fecal/biliary: negligible; absorbed drug not excreted renally is retained in bone with slow release.
Renal: 50-60% unchanged drug; biliary/fecal: <5%
Category C
Category C
Bisphosphonate
Bisphosphonate